MartinFrederikDietrichMDPhD

Oncology • Rockledge, FL

Breast Cancer, Thoracic Cancer

Medical Oncologist

Join to view full profile

Dr. Dietrich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dietrich's full profile

Already have an account?

Office
1048 Harvin Way
Rockledge, FL 32955
Phone+1 321-636-2111

Fax+1 321-636-7180

Education & Training

University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2010 - 2012
Ruprecht Karl University Faculty of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2016 - 2026
TX State Medical License 2012 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
Karolina A Kilowski, Martin F Dietrich, Joanne Xiu, Yasmine Baca, Andrew Hinton
Gynecologic Oncology. 2024-12-01
A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Christina Baik, Michael L Cheng, Martin Dietrich, Jhanelle E Gray, Nagla A Karim
Advances in Therapy. 2024-07-01
Correction to: A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600EMutant Metastatic Non-Small Cell Lung Cancer.
Christina Baik, Michael L Cheng, Martin Dietrich, Jhanelle E Gray, Nagla A Karim
Advances in Therapy. 2024-07-01

Press Mentions

FDA Expands Indication for Amivantamab in Lung CancerSeptember 23rd, 2024
JnJ Gets USFDA Nod for Rybrevant plus Standard of Care Chemotherapy for Lung Cancer TreatmentSeptember 21st, 2024
RYBREVANT® (Amivantamab-Vmjw) plus Standard of Care Approved in the U.S. As First and Only Targeted Regimen to Cut Risk of Disease Progression by More Than Half in Second-Line EGFR-Mutated Advanced Lung CancerSeptember 19th, 2024
Join now to see all